Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Inclusion Criteria :

1. Voluntarily sign informed consent forms before any investigational procedure(s) areperformed.

2. Male or female aged between 18 and 75 years at the time of signing the informedconsent.

3. Clinical diagnosis of PN by a dermatologist for at least 3 months before theScreening visit.

4. At least 20 pruriginous lesions on the entire body with a bilateral distribution (onboth legs, and/or both arms and/or trunk) at both screening and the baseline (Day 1)visits.

5. PP NRS score ≥ 7 at both screening and the baseline (Day 1) visits.

6. IGA-CPG-S score ≥ 3 at both the screening and the baseline (Day 1) visits.

7. History of inadequate response to topical corticosteroid of medium or higher potencyor for whom topical treatments are otherwise medically inadvisable (e.g., because ofimportant side effects or safety risks).

Willingness to avoid pregnancy or fathering children

Exclusion Criteria:

1. Patients with a documented AD severity moderate to severe presence of skinmorbidities other than PN and mild AD that may interfere with the assessment of thestudy outcomes. PN secondary to medications .

2. Any uncontrolled or serious disease, or any medical, psychological, or surgicalcondition including relevant laboratory abnormalities at screening that may eitherinterfere with the interpretation of the clinical trial results and/or, in theinvestigator's judgment, would adversely affect the patient's participation in thestudy. Active chronic or acute infection participant not suitable for participation,whatever the reason, as judged by the Investigator, including medical or clinicalconditions, or participants potentially at risk of noncompliance to studyprocedures.